Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of ADHD Treatment Response
NCT05650775Phase 1Completed
- Sponsor
- Boston Children's Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of methylphenidate osmotic release oral system and mixed salts of a single-entity amphetamine product extended-release capsules in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Boston Children's Hospital. Primary endpoints: Change in ADHD Symptom Severity from Baseline to End of Concerta Trial at 3 weeks, Change in ADHD Symptom Severity from Baseline to End of Adderall-XR Trial at 3 weeks and 8 more. Started Feb 2023; status: completed.
02
Drugs
methylphenidate osmotic release oral systemmixed salts of a single-entity amphetamine product extended-release capsules
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05650775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650775.